Discover how the three largest pharmacy benefit managers are rejecting biosimilars from their formularies, except for their own private-label drugs.

MedPlus continued to benefit from strong sales of products under its private label brands in both the pharmaceuticals and consumer wellness categories ...

On December 27, 2024, the US Food and Drug Administration (FDA) published its final rule to update the definition for “healthy” claims on food ...

The Food and Drug Administration on Thursday approved a new type of nonopioid painkiller from Vertex Pharmaceuticals, NBC News reported. The drug, Journavx, or suzetrigine, was approved to treat ...

Q4 2024 Earnings Call Transcript February 12, 2025 Ascendis Pharma A/S beats earnings expectations. Reported EPS is $-0.68699 ...

In the Guidance, the FDA posits that poor pharmaceutical label design can contribute to ... setting up one of the largest private equity buyouts in Japan's health sector.

Irv Gotti will be laid to rest in a private funeral service in his hometown of New York, attended by close friends and family ...

Acceptance follows resolution of third-party fill/finish manufacturing issues FDA decision expected by July 10, 2025 TARRYTOWN, N.Y., Feb. 11, 2025 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc.

Acceptance follows resolution of third-party fill/finish manufacturing issuesFDA decision expected by July 10, 2025 TARRYTOWN, N.Y., Feb. 11, ...

MedPlus continued to benefit from strong sales of products under its private label brands in both the pharmaceuticals and consumer wellness categories, which analysts say contribute more to its ...

Investigational Review Board (IRB) approval has been granted for the open-label study to evaluate tafenoquine for treatment of patients with a ...

Robin Fields ProPublica is a nonprofit newsroom that investigates abuses of power. Sign up to receive our biggest stories as ...